Sunday, October 11, 2026

Moderna Stock Is 5.22% Up So Far Today

ViaNews Editorial Team

November 20, 2020

Moderna Stock Is 5.22% Up So Far Today

According to today's article on Bloomberg Quint, "EU Could Approve BioNTech, Moderna Vaccines in December."

Shares of Moderna rose 5.22% to $97.61 at 17:05 EST on Friday, after one sequential sessions in a rows of gains. The Nasdaq Stock Market is sliding 0.42% to $11855, after one consecutive sessions in a rows of gains, on what seems, so far, a somewhat negative trend exchanging session on The Nasdaq Stock Market.

According to yesterday's article on Bloomberg Quint, "Moderna Vaccine Production Is Gearing Up, Partner Lonza Says."

Moderna's last close was $92.77, below its 52-week high of $103.2.

Moderna's sales growth is 1216.8% for the current quarter and 2299% for the next. The company's growth estimates for the ongoing quarter is a negative 67.6% and positive 142.9% for the next.

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's stock is valued at $97.61 at 17:05 EST, below its 52-week high of $103.2 and way above its 52-week low of $17.68.

Moderna's value is way higher than its 50-day moving average of $75.37 and way above its 200-day moving average of $68.93.

Moderna vaccine found highly effective at preventing covid. According to Bloomberg Quint on Mon Nov 16, "Moderna shares rised more than 9% in pre-market U.S."

According to MarketWatch on Mon Nov 16, "Stock futures surge as Moderna says coronavirus vaccine is 94.5% effective in trial."

Moderna shares soar premarket after coronavirus vaccine candidate achieves 94.5% efficacy in phase 3 trial. According to MarketWatch on Mon Nov 16, "Moderna Inc"

Update: Moderna shares soar premarket after coronavirus vaccine candidate achieves 94.5% efficacy in phase 3 trial. According to MarketWatch on Mon Nov 16, "Moderna Inc"

According to MarketWatch on Mon Nov 16, "Moderna shares have surged 18% in premarket on coronavirus vaccine trial data."

Stocks making the biggest moves in the premarket: Moderna, casper sleep, Uber, tapestry & more. According to CNBC on Mon Nov 16, "The stocks making the biggest moves in premarket trading include Moderna, Casper Sleep, Uber, Tapestry, and more.."

According to Bloomberg Quint on Mon Nov 16, "NYC-Linked Stocks Climb on Optimism Over Moderna Vaccine Results."

Stocks making the biggest moves midday: Moderna, simon property, bbva, virgin galactic & more. According to CNBC on Mon Nov 16, "Moderna gets a boost from positive vaccine trial data."

According to Bloomberg Quint on Mon Nov 16, "European Stocks Surge to February High on Moderna Vaccine Study."

According to Bloomberg Quint on Mon Nov 16, "Moderna Adds to Vaccine Hope; New California Curbs: Virus Update."

According to Bloomberg Quint on Tue Nov 17, "Moderna Vaccine Offers Possible Antidote to Deep-Freeze Problem."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,369 source documents archived
Query this data → isubstrate.com